A carregar...
Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe
Crizotinib (XALKORI(®)) is indicated for anaplastic lymphoma kinase‐positive and ROS1‐positive advanced non‐small cell lung cancer. This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cross‐secti...
Na minha lista:
| Publicado no: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7105834/ https://ncbi.nlm.nih.gov/pubmed/32232958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.570 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|